Clinical Trial: Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC

U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07500987) titled 'Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC' on Feb. 18.

Brief Summary: This is a Phase I, multicentre, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, PD, and PK of [111In]-FPI-2107 after pre-dose administration of FPI-2053 in Chinese participants with EGFR mutation-positive NSCLC.

Study Start Date: Feb. 27

Study Type: INTERVENTIONAL

Condition: EGFR Mutation-positive NSCLC

Intervention: DRUG: [111In]-FPI-2107

radioimmuno-SPECT agent

DRUG: FPI-2053

unconjugated/unlabelled bispecific antibody [cold]

Recruitment Status: RECRUITING

Sponsor: AstraZ...